Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer

Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer

New therapeutic targets are revolutionizing colorectal cancer clinical management, opening new horizons in metastatic patients’ outcome. Polo Like Kinase1 (PLK1) inhibitors have high potential as antitumoral agents, however, the emergence of drug resistance is a major challenge for their use in clin...

Full description

Saved in:
Bibliographic Details
Main Authors: Sonia Solanes-Casado, Arancha Cebrián, María Rodríguez-Remírez, Ignacio Mahíllo, Laura García-García, Anxo Río-Vilariño, Natalia Baños, Guillermo de Cárcer, Ana Monfort-Vengut, Víctor Castellano, Maria Jesús Fernández-Aceñero, Jesús García-Foncillas, Laura del Puerto-Nevado
Format: article
Language:EN
Published: Elsevier 2021
Subjects:
Colorectal cancer (CRC)
Polo-Like Kinase 1 (PLK1)
BI2536
Drug resistance
Re-sensitization
Simvastatin
Therapeutics. Pharmacology
RM1-950
Online Access:https://doaj.org/article/7e7044e51a4443f1bd9c0e6e88deaf7a
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/7e7044e51a4443f1bd9c0e6e88deaf7a

Similar Items